Document is current
Any future updates will be listed below
-
Authors
Åkesson, Julia https://orcid.org/0000-0002-9276-0546
Hojjati, Sara
Hellberg, Sandra
Raffetseder, Johanna https://orcid.org/0000-0001-8871-2560
Khademi, Mohsen https://orcid.org/0000-0003-0801-1444
Rynkowski, Robert
Kockum, Ingrid https://orcid.org/0000-0002-0867-4726
Altafini, Claudio https://orcid.org/0000-0003-4142-6502
Lubovac-Pilav, Zelmina https://orcid.org/0000-0001-6427-0315
Mellergård, Johan https://orcid.org/0000-0003-0120-3734
Jenmalm, Maria C. https://orcid.org/0000-0002-2117-5366
Piehl, Fredrik https://orcid.org/0000-0001-8329-5219
Olsson, Tomas
Ernerudh, Jan https://orcid.org/0000-0001-9456-2044
Gustafsson, Mika https://orcid.org/0000-0002-0048-4063
- License Information
-
More Information
Article History
Received: 10 March 2023
Accepted: 17 October 2023
First Online: 30 October 2023
Competing interests
: T.O. has received advisory board/lecture honoraria as well as unrestricted research grants from Biogen, Novartis, Sanofi, and Merck. None of which has any relation to the current manuscript. F.P. has received research grants from Janssen, Merck KgaA and UCB, and fees for serving on DMC in clinical trials with Chugai, Lundbeck and Roche, and preparation of expert witness statement for Novartis. J.M. has received honoraria for advisory boards for Sanofi Genzyme and Merck and lecture honorarium from Merck. The remaining authors declare no competing interests.
: This study was reviewed and approved by the regional ethics review board in Linköping Sweden (2013/155-32, 2016/304-32, 2016/305-32, 2014/311-31, 2017/288-31) and the ethics review board in Stockholm Sweden (2022-03650-02). The participants provided their written informed consent to participate in this study.
